
Navenibart Cuts HAE Attacks by 90% or More: Aleena Banerji, MD
Aleena Banerji, MD, discusses ALPHA-SOLAR interim data on navenibart dosed every 3 or 6 months for hereditary angioedema prevention at ACAAI 2026.
Navenibart, an investigational long-acting monoclonal antibody inhibitor of plasma kallikrein, reduced hereditary angioedema (HAE) attack rates by at least 90% with dosing every 3 or 6 months in interim results from the open-label ALPHA-SOLAR extension trial.1 Aleena Banerji, MD, professor of medicine at Harvard Medical School and clinical director of the Allergy and Clinical Immunology Unit at Massachusetts General Hospital, discussed the findings in an interview.
Banerji presented the interim data at the
"I think there is a lot of benefit to having a drug that is dosed infrequently, right? We are talking about 2 to 4 injections in a year. And so I think the treatment burden is something that comes up a lot with our patients with hereditary angioedema," Banerji said.
Mean and median attack rates fell 92% and 97% in Arm A and 90% and 97% in Arm B from ALPHA-STAR baseline, and mean moderate or severe attack rates declined from 1.6 to 0.09 in Arm A and from 0.77 to 0.08 in Arm B.1 At 6 months, mean Angioedema Quality of Life Questionnaire (AE-QoL) total scores improved by 30.1 points in Arm A and 30.5 points in Arm B, exceeding the 6-point minimal clinically important difference.
Treatment-emergent adverse events (AEs) occurred in 69% of patients and were mostly mild, and Banerji said no drug-related serious AEs had been reported, with little difference between dosing arms to date. Navenibart is being evaluated in the phase 3 ALPHA-ORBIT (NCT06842823) and ORBIT-EXPANSE (NCT07204938) trials.1 These interim, open-label data have not been peer reviewed.
Banerji’s disclosures include Astria, Intellia, and Ionis.
References
Banerji A, Adatia A, Jacobs J, et al. Long-term safety, efficacy, and quality of life with navenibart in hereditary angioedema: ALPHA-SOLAR interim results. Ann Allergy Asthma Immunol. 2026;137:S47. Abstract R110.
HAE in 2026: new therapies, updated guidelines, the case for early treatment. HCPLive. May 11, 2026. Accessed November 15, 2026. https://www.hcplive.com/view/hae-2026-new-therapies-updated-guidelines-the-case-early-treatment
Related to this article








